Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Advanced Stage at Diagnosis and Worse Clinicopathologic Features in Young Women with Breast Cancer in Brazil: A Subanalysis of the AMAZONA III Study (GBECAM 0115).
Franzoi MA, Rosa DD, Zaffaroni F, Werutsky G, Simon S, Bines J, Barrios C, Cronemberger E, Queiroz GS, Cordeiro de Lima V, Júnior RF, Couto J, Emerenciano K, Resende H, Crocamo S, Reinert T, Van Eyli B, Nerón Y, Dybal V, Lazaretti N, de Cassia Costamillan R, Pinto de Andrade DA, Mathias C, Vacaro GZ, Borges G, Morelle A, Filho CAS, Mano M, Liedke PER. Franzoi MA, et al. Among authors: morelle a. J Glob Oncol. 2019 Nov;5:1-10. doi: 10.1200/JGO.19.00263. J Glob Oncol. 2019. PMID: 31730380 Free PMC article.
[Age as a prognostic factor in early breast cancer].
Garicochea B, Morelle A, Andrighetti AE, Cancella A, Bós A, Werutsky G. Garicochea B, et al. Among authors: morelle a. Rev Saude Publica. 2009 Apr;43(2):311-7. doi: 10.1590/s0034-89102009005000009. Epub 2009 Mar 6. Rev Saude Publica. 2009. PMID: 19225690 Free article. Portuguese.
The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115).
Rosa DD, Bines J, Werutsky G, Barrios CH, Cronemberger E, Queiroz GS, de Lima VCC, Freitas-Júnior R, Couto JD, Emerenciano K, Resende H, Crocamo S, Reinert T, Van Eyil B, Nerón Y, Dybal V, Lazaretti N, de Cassia Costamilan R, de Andrade DAP, Mathias C, Vacaro GZ, Borges G, Morelle A, Caleffi M, Filho CS, Mano MS, Zaffaroni F, de Jesus RG, Simon SD. Rosa DD, et al. Among authors: morelle a. Breast Cancer Res Treat. 2020 Oct;183(3):749-757. doi: 10.1007/s10549-020-05831-y. Epub 2020 Jul 29. Breast Cancer Res Treat. 2020. PMID: 32728860
Management of patients with recurrent/metastatic endometrial cancer: Consensus recommendations from an expert panel from Brazil.
de Andrade DAP, Guimarães APG, de Melo AC, Nogueira-Rodrigues A, Gomes LM, Scaranti M, Maia JML, Morelle AM, Santos CAAL, Souza CP, de Freitas D, Callegaro Filho D, Paulino E, Júnior EWA, Pimenta JM, Dos Santos MB, de Almeida MS, Souza RP, Cabral S, Maluf FC. de Andrade DAP, et al. Among authors: morelle am. Front Oncol. 2023 Mar 9;13:1133277. doi: 10.3389/fonc.2023.1133277. eCollection 2023. Front Oncol. 2023. PMID: 36969061 Free PMC article.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Gligorov J, et al. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. Eur J Cancer. 2017. PMID: 28625777 Clinical Trial.
Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects.
Isaacsson Velho P, Bastos DA, Saint'ana PT, Rigatti B, da Costa ET, Muniz DQB, Andreis F, Ferreira RDP, Giongo Pedrotti L, Maistro S, Katayama MLH, Folgueira MAAK, Morelle A, Leal A, de Castro G Jr. Isaacsson Velho P, et al. Among authors: morelle a. Clin Cancer Res. 2024 Dec 2;30(23):5342-5352. doi: 10.1158/1078-0432.CCR-24-1595. Clin Cancer Res. 2024. PMID: 39330991 Clinical Trial.
15 results